본문 바로가기
bar_progress

Text Size

Close

Samyang Group Conducts Regular Executive Personnel Changes... Strengthening Global Specialty Business

Chemical Group 1 and Chemical Group 2 Separate Management

Samyang Group has carried out its regular executive appointments and organizational restructuring. This is the first personnel and organizational change since the group's 100th anniversary, aimed at strengthening the group's core businesses in 'global' and 'specialty (high-functionality)' sectors.


Samyang Group Conducts Regular Executive Personnel Changes... Strengthening Global Specialty Business Samyang Group Corporate Identity (CI)

First, the Chemical Group has been divided into Chemical Group 1 and Chemical Group 2 to enhance management efficiency. Chemical Group 1 includes traditional chemical material businesses centered around Samyang Corporation, such as Samyang Inochem, Samyang Hwasung, Samyang Hwaintechnology, and Samnam Petrochemical. Chemical Group 2 consists of affiliates engaged in specialty businesses, including Samyang NChem, the largest domestic semiconductor photoresist (PR) material specialist, KCI, a personal care material specialist, and Verdant, a global chemical company acquired last year.


Chemical Group 1 will be led by CEO Kang Hoseong, the former head of the Chemical Group, while Chemical Group 2 will be headed by Kim Gunho, Chief Strategy Officer of Samyang Holdings, who will concurrently serve as group leader to further grow the related businesses.


The Biopharm Group has newly appointed Kim Kyungjin, former CEO of ST Pharm, as group leader. Group Leader Kim Kyungjin has been recognized for his excellent capabilities both as a researcher and a professional manager, having served as a senior researcher at global pharmaceutical company Roche, and held positions such as Head of Synthesis Research Department 1, Director of the Research Institute, and CEO at ST Pharm. Appointed as the Biopharm Group Leader of Samyang Holdings, he is expected to expand the global market, strengthen expertise in Contract Development and Manufacturing Organization (CDMO), and accelerate research and development of mRNA delivery systems.


Additionally, among the six newly appointed executives excluding external hires, three are in their 40s and will take on key roles within the group. Samyang Group stated that it focused on selecting personnel differentiated by expertise and leadership based on performance rather than seniority. The regular executive appointments will take effect on the 1st of next month.


The following is the list of new executives.


◆ Samyang Holdings

△ Kim Kyungjin, Biopharm Group Leader, President (external hire)

△ Lee Soobeom, Head of HRC


◆ Samyang Corporation

△ Yoon Kyungsoo, Head of Food Support PU

△ Moon Woosik, Head of Incheon Plant 1

△ Han Jungsook, Head of Food Research Institute


◆ Samyang Packaging

△ Yoon Kwangseok, Head of Aseptic Sales PU


◆ Samyang Hwasung

△ Lee Younghoon, CEO


© The Asia Business Daily(www.asiae.co.kr). All rights reserved.


Join us on social!

Top